Currrent Issue: Volume 3, Number 2, 2015


Article

Tumor Protein p53: Novel Aspects of an Old Tumor Marker

1Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia

2Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt


Journal of Cancer Research and Treatment. 2015, 3(2), 25-27
doi: 10.12691/jcrt-3-2-2
Copyright © 2015 Science and Education Publishing

Cite this paper:
Ahmed M. Kabel. Tumor Protein p53: Novel Aspects of an Old Tumor Marker. Journal of Cancer Research and Treatment. 2015; 3(2):25-27. doi: 10.12691/jcrt-3-2-2.

Correspondence to: Ahmed  M. Kabel, Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia. Email: drakabel@gmail.com

Abstract

P53 gene is a tumor suppressor gene that stops the formation of tumors. If a person inherits only one functional copy of the p53 gene from his parents, he will be predisposed to cancer and usually develop several tumors in various tissues in early adulthood. However, mutations in p53 are found in most tumor types, and so contribute to a number of molecular events leading to tumor formation. There are numerous informations that exist on all aspects of p53 normal function and mutant expression in human cancers, reflecting its key role in the pathogenesis of human cancers.

Keywords

References

[1]  Surget S, Khoury MP, Bourdon JC (2013). Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. OncoTargets and Therapy; 7: 57-68.
 
[2]  Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, Baer R, Gu W (2015). Ferroptosis as a p53-mediated activity during tumour suppression. Nature; 520 (7545):57-62.
 
[3]  Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP et al. (2005). p53 isoforms can regulate p53 transcriptional activity. Genes & Development; 19 (18): 2122-37.
 
[4]  Abdel-Rahman MN, Kabel AM (2012). Comparative study between the effect of methotrexate and valproic acid on solid Ehrlich tumour. J Egypt Natl Canc Inst; 24(4):161-7.
 
[5]  Larsen S, Yokochi T, Isogai E, Nakamura Y, Ozaki T, Nakagawara A (2010). LMO3 interacts with p53 and inhibits its transcriptional activity. Biochem Biophys Res Commun; 392 (3): 252-7.
 
Show More References
[6]  Harms KL, Chen X (2005). The C Terminus of p53 Family Proteins Is a Cell Fate Determinant. Mol Cell Biol; 25 (5): 2014-30.
 
[7]  Bell S, Klein C, Müller L, Hansen S, Buchner J (2002). p53 contains large unstructured regions in its native state. J Mol Biol; 322 (5): 917-27.
 
[8]  Khoury MP, Bourdon J-C (2011). p53 Isoforms: An Intracellular Microprocessor?. Genes Cancer; 2(4): 453-465.
 
[9]  Zhu J, Zhang S, Jiang J, Chen X (2000). Definition of the p53 functional domains necessary for inducing apoptosis. The Journal of Biological Chemistry; 275 (51): 39927-34.
 
[10]  Bourdon JC (2007). p53 and its isoforms in cancer. Br J Cancer; 97(3):277-82.
 
[11]  Hasty P, Christy BA (2013). p53 as an intervention target for cancer and aging. Pathobiology of Aging & Age Related Diseases; 3:10.3402/pba.v3i0.22702.
 
[12]  Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J et al. (2009). "MiR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities". Leukemia, U.K.; 23 (6): 1159-63.
 
[13]  Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE et al. (2007). Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell; 128 (5): 853-64.
 
[14]  Han ES, Muller FL, Pérez VI, Qi W, Liang H, Xi L et al. (2008). The in vivo Gene Expression Signature of Oxidative Stress. Physiol Genomics; 34 (1): 112-26.
 
[15]  Loughery J, Cox M, Smith LM, Meek DW (2014). Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters. Nucl Acids Res; 2014.
 
[16]  Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T, Kubin T et al. (2008). Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res; 102 (6): 703-10.
 
[17]  Monique G. C. T. van Oijen MGCT, Slootweg PJ (2000). Gain-of-Function Mutations in the Tumor Suppressor Gene p53. Clin Cancer Res; 6:2138.
 
[18]  Herce HD, Deng W, Helma J, Leonhardt H, Cardoso MC (2013). Visualization and targeted disruption of protein interactions in living cells. Nat Commun; 4: 2660.
 
[19]  White EA, Walther J, Javanbakht H, Howley PM (2014). Genus Beta Human Papillomavirus E6 Proteins Vary in Their Effects on the Transactivation of p53 Target Genes. J Virol; 88(15): 8201-12.
 
[20]  Angeletti PC, Zhang L, Wood C (2008). "The Viral Etiology of AIDS-Associated Malignancies". Adv Pharmacol; 56: 509-57.
 
[21]  Muller PAJ, Vousden KH (2014). Mutant p53 in Cancer: New Functions and Therapeutic Opportunities. Cancer Cell; 25(3):304-317.
 
Show Less References

Article

Exploration of Cognitive Functioning in a Pilot Sample of Childhood Cancer Patients in Egypt

1Child Health Department, National Research Center, 33 Elbehouth street Dokki, Giza, Egypt

2Pediatric Oncology Department, National Cancer Institute, Cairo University, Fom El Khalig Square Kornish El Nil, Cairo, Egypt

3Environmental and Occupational Medicine Department, National Research Center, 33 Elbehouth street, Dokki, Giza, Egypt


Journal of Cancer Research and Treatment. 2015, 3(2), 19-24
doi: 10.12691/jcrt-3-2-1
Copyright © 2015 Science and Education Publishing

Cite this paper:
Manal A. Shehata, Mohamed Fawzy, Mai S. Saleh, Zeinab M. Monir, Hanafy Ahmed. Exploration of Cognitive Functioning in a Pilot Sample of Childhood Cancer Patients in Egypt. Journal of Cancer Research and Treatment. 2015; 3(2):19-24. doi: 10.12691/jcrt-3-2-1.

Correspondence to: Mai  S. Saleh, Environmental and Occupational Medicine Department, National Research Center, 33 Elbehouth street, Dokki, Giza, Egypt. Email: nouranomer@gmail.com

Abstract

A subset of cancer survivors experience cognitive deficits that can last for many years after the completion of chemotherapy. The etiology of this problem is largely unknown, so the present study aimed to assess cognitive functioning in childhood patients with cancer and to investigate the proposed disposing factors including variables related to disease, treatment, and some socio-demographic characteristics. In a case control study parents of 67 cancer patients aged 8-12 years, completed the parent proxy report of PedsQL™ 3.0 Cognitive Functioning Scale (Arabic versions), as well as a separate sheet for socio-demographic data. Control group consisted of 37 healthy subjects from the same age group were subjected to the same methodology for comparison. All patients under the study have successfully accomplished their treatment protocol and were in complete remission during the evaluation. Hematological malignancies represented 70.1% of the patients sample, with the highest proportion for ALL (52.2%). Brain tumors represented 40% of the solid malignancies (29.9% of the study patients). Cognitive functioning score was significantly lower in the solid group (69.6±37.3) compared to the hematologic group (85.1±22.2) (t = 2.1, p =0.038). Cognitive functioning score was also lower in solid group versus control subjects (p =0.047), while it showed no significant difference between hematological malignancies and control group. Older age at diagnosis, urban residence, illiterate mothers, higher duration of treatment as well as long duration of hospital admission were associated with a lower cognitive score in the solid tumors group compared to hematological group.

Keywords

References

[1]  Yaris N, Mandiracioglu A, Büyükpamukcu M. Childhood cancer in developing countries. PediatrHematolOncol 2004; 21:237-253.
 
[2]  Steliarova-Foucher E, Hery C, Pisani P. Childhood cancer: rising to the challenge. UICC; Geneva. The burden of childhood cancer 2006; pp. 9-14.
 
[3]  Conklin HM, Krull KR, Reddick W E, et al. Cognitive Outcomes Following Contemporary Treatment Without Cranial Irradiation for Childhood Acute Lymphoblastic Leukemia. J Natl Cancer Inst.2012; 104:1386-1395.
 
[4]  Bender CM, Paraska KK, Sereika SM, et al. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage 2001; 21: 407-424.
 
[5]  Moore BD 3rd. Neurocognitive outcomes in survivors of childhood cancer. J PediatrPsychol 2005; 30(1):51-63.
 
Show More References
[6]  Jansen CE, Miaskowski C, Dodd M, et al. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. CANCER 2005; 104 / 10: 2222-2233.
 
[7]  Fardell JE., Vardy J, Johnston I N, et al. Chemotherapy and Cognitive Impairment: Treatment Options. Clinical pharmacology & Therapeutics 2011; 90 NUMBER 3.
 
[8]  Pui CH, Schrappe M, Masera G, et al. Ponte di Legno Working Group: statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop. Leukemia 2004; 18: 1043-1053.
 
[9]  Pui CH, Ribeiro RC. International collaboration on childhood leukemia. Int J Hematol 2003; 78: 383-389.
 
[10]  Ribeiro RC and Pui CH. Saving the Children — Improving Childhood Cancer Treatment in Developing Countries. N Engl J Med 2005; 352:2158-2160.
 
[11]  Varni, JW, Limbers CA., Sorensen LG, et al. PedsQL™ Cognitive Functioning Scale in pediatric liver transplant recipients: Feasibility, reliability and validity. Quality of Life Research 2011; 20: 913-921.
 
[12]  Varni JW, Burwinkle TM, Seid M, et al. The PedsQLÔ 4.0 as a pediatric population health measure: Feasibility, reliability, and validity. Ambulatory Pediatrics 2003; 3: 329-341.
 
[13]  Sprangers M, Cull A, Groenvold M, et al. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: An update and overview. Quality of Life Research 1998; 7: 291-300.
 
[14]  Magal-Vardi O, Laor N, Toren A, et al. Psychiatric morbidity and quality of life in children with malignancies and their parents. The Journal of Nervous and Mental Disease 2004;. 92:872-875.
 
[15]  Landolt MA, Vollrath M, Niggli FK, et al. Health-related quality of life in children with newly diagnosed cancer: a one year follow-up study. Health and Quality of Life Outcomes 2006; 4:63.
 
[16]  Vardy J, Wefel JS, Ahles T, et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Annals of Oncology 2008; 19: 623-629.
 
[17]  14 Butler RW, Haser JK. Neurocognitive effects of treatment for childhood cancer mental retardation and developmental disabilities research reviews 2006;.12: 184-191.
 
[18]  Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J ClinOncol 2000;18: 2695-2701.
 
[19]  Ahles TA, Saykin AJ, Furstenberg CT et al. Neuropsychologic impact of standard dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J ClinOncol. 2002; 20: 485-493.
 
[20]  Tchen N, Juffs HG, Downie FP et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J ClinOncol 2003; 21: 4175-4183.
 
[21]  Von derWeid N, Mosimann I, Hirt A, et al. Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: Age- and sex-related differences. Eur J Cancer 2003; 39: 359-365.
 
[22]  Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J. Clin. Exp. Neuropsychol. 2004; 26: 955-969.
 
[23]  Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006; 94(6): 828-34.
 
[24]  Donovan KA, Small BJ, Andrykowski MA, et al. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005; 104(11): 2499-507.
 
[25]  Copeland DR, Fletcher JM, Pfefferbaum-Levine B, et al. Neuropsychological sequelae of childhood cancer in long-term survivors. Pediatrics.1985; 75:745-753.
 
[26]  Butler RW, Hill JM, Steinherz PG, et al. Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J Clin Oncol.1994; 12: 2621-2629.
 
[27]  AndersonV, Godber T, Smibert E, et al. Neurobehaviouralsequelae following cranial irradiation and chemotherapy in children: An analysis of risk factors. PediatrRehabil. 1997; 1:63-76.
 
[28]  Peckham VC. Learning disorders associated with the treatment of cancer in childhood. Journal of the Association of Pediatric Oncology Nursing 1988; 5: 10-13.
 
[29]  Peckham VC. Learning disabilities in long-term survivors of childhood cancer: Concerns for parents and teachers. Reading, Writing and Learning Disabilities 1989; 5: 313-325.
 
[30]  Whittington E: Survivors at Risk for Cognitive Dysfunction. Cure, 2007 http://www.curetoday.com/index.cfm/fuseaction/article.PrintArticle/article_id/111. Last accessed November, 2013.
 
[31]  Nathan PC, Patel SK, Dilley K, et al.Guidelines for Identification of, Advocacy for and Intervention in Neurocognitive Problems in Survivors of Childhood Cancer. Arch PediatrAdolesc Med. 2007; 161(8): 798-806.
 
[32]  Spencer J. The Role of Cognitive Remediation in Childhood Cancer Survivors Experiencing Neurocognitive Late Effects. Journal of Pediatric Oncology Nursing 2006; 23(6): 321-325.
 
[33]  Vanderploeg RD, Schinka JA, Baum KM, et al. WISC-III premorbid prediction strategies: demographic and best performance approaches. Pychol Assess.1998; 10 (3):277-284.
 
[34]  Wells NM. At home with nature: effects of “greenness” on children’s cognitive functioning. Environ. Behav.2000; 32 (6):775-795.
 
[35]  Buizer AI, de Sonneville LM, van den Heuvel-Eibrink MM, et al. Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: Effect of treatment intensity.Pediatr Blood Cancer 2005; 45:281-290.
 
Show Less References

SciEP events

To list your link on our website, please click here or contact us
Doing on SciEP